Article Text

FRI0375 Flow-Based Cell-Specific Interferon Signature as a Biomarker in Systemic Lupus Erythematosus
  1. Y. El-Sherbiny1,2,
  2. A.A. Mohamed1,
  3. Y.M. Yusof1,2,
  4. E. Vital1,2,
  5. P. Emery1,2
  1. 1Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds
  2. 2NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom


Background Type I interferons (IFNs) have been confirmed to play a pivotal role in the pathogenesis of Systemic lupus erythematosus (SLE) and Rheumatoid arthritis (RA). IFN activity is usually monitored using a whole blood signature of IFN responsive genes. However; (i) these signatures do not correlate with disease activity, (ii) they also do not predict response to anti-IFN therapy. This may be because IFN response varies in different cell populations whose frequency varies in different disease states. We therefore sought a cell specific IFN signature using surface expression of the IFN response protein, Siglec-1 (sialoadhesin, CD169), which represents type I IFN activity on monocytes. B cells are involved in both diseases and have been target of therapy by different biologics. Changes in B cell subsets (esp. plasmablast (PB) expansion) are associated with disease activity. Hence, we investigated the correlation of different B cell subsets with the level of Siglec-1 in RA and SLE patients.

Objectives To study the use of a flow cytometry cell specific assay for interferon signature in SLE.

Methods Peripheral blood was collected from 27 SLE patients, 18 RA patients and 5 healthy controls (HC) and was analyzed for the level of Siglec-1 (CD169) expression on monocytes as well as for the numbers of naïve, memory and PB B cell subsets using multi-parameter flow cytometry using panels including: CD19, CD27, CD38, CD3, CD4, CD8, CD16, CD14, CD56, CD64, CD69 and CD169. Disease activity was measured by BILAG-2004 for SLE patients and DAS-28 for RA patients.

Results Siglec-1 was found significantly higher in SLE and RA than in HC (p=0.03) (ANOVA test). However, no significant difference was found between RA and SLE Siglec-1 expression. In SLE patients, Siglec-1 was found significantly higher in patients with high BILAG score (n=6) than those with low BILAG (n=17) (p=0.0002) (Mann Whitney test). Moreover, Siglec-1 was significantly correlated with levels of autoantibodies in SLE patients (P=0.0175, r=0.634) (Spearman); the number of autoantibody positivity was associated with higher Siglec-1 expression on monocytes.

Although BILAG score was significantly correlated with percentage of PB in SLE patients' blood (p=0.008, r=0.681) (Spearman R), we found no significant correlation between PB numbers or other cell subsets and Siglec-1 levels on monocytes. Interestingly, CD64 on monocytes was also upregulated in SLE and significantly correlated with Siglec-1.

Conclusions Monocyte Siglec-1 expression level as a measure of type I IFN activity were correlated with the disease activity and the number of autoantibody positivity in SLE. However, it does not explain the characteristic changes in B cell differentiation. Moreover, it does not act as a disease specific marker since it was invariably high in the active state of both diseases.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.